Hormone-suppressing drug improves cognition in aged dogs
Older dogs forget, lose focus, and react more slowly, much like humans experiencing cognitive aging. A drug that damps down a growth hormone pathway improved those functions in elderly dogs in a controlled trial.
Elevated growth hormone and IGF-1 (a signalling protein that regulates cell growth) are associated across multiple species with shorter lifespan and poorer late-life cognition. The study, published in Frontiers in Veterinary Science, tested octreotide, a long-acting drug that suppresses growth hormone and IGF-1 production, in 28 aged beagles between 7 and 15 years old.
How the study was designed
The trial was randomised and placebo-controlled. After a 28-day baseline, dogs received either an octreotide injection or a placebo, followed by a wash-in interval and 28 days of post-treatment testing. A validated cognitive battery assessed three functions: executive control and flexibility (switching learned rules), selective attention, and visuospatial working memory.
Dogs receiving octreotide performed significantly better than the placebo group across all three tasks. The primary effect was faster response latency and greater task engagement, rather than a higher proportion of correct answers per se.
What this says about growth hormone and aging
The researchers describe the dog as a valuable translational model: its brain aging and dementia-like changes closely parallel those seen in humans. Whether this drug could slow cognitive decline in humans cannot be concluded from this study. The trial involved 28 animals; larger follow-up studies are needed.
Want to research this yourself?
Search for example:
- somatotropic signaling cognitive aging
- IGF-1 suppression brain aging
- translational animal model dementia